Palisade Bio Advances PALI-2108 Into Phase 2 IBD Trials
DENVER, Colorado, August 10, 2026 Palisade Bio, Inc. announced its second-quarter 2026 financial results and provided a business update...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DENVER, Colorado, August 10, 2026 Palisade Bio, Inc. announced its second-quarter 2026 financial results and provided a business update...
HONG KONG, July 8, 2026 Sino Biopharmaceutical Limited has announced that its subsidiary, Chia Tai Tianqing Pharmaceutical Group Co.,...
DENVER, Colo., June 29, 2026 Palisade Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared...
WESTLAKE VILLAGE, Calif., June 29, 2026 Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has...
CHICAGO, Ill., June 20, 2026 The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology...
SAN DIEGO, Calif., June 20, 2026 cAMPfield Therapeutics has officially emerged from stealth with a $180 million Series A...
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
